Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy. Reasons for discontinuation in clinical practice have not been adequately studied. We conducted a retrospective analysis of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mato, Anthony R., Nabhan, Chadhi, Thompson, Meghan C., Lamanna, Nicole, Brander, Danielle M., Hill, Brian, Howlett, Christina, Skarbnik, Alan, Cheson, Bruce D., Zent, Clive, Pu, Jeffrey, Kiselev, Pavel, Goy, Andre, Claxton, David, Isaac, Krista, Kennard, Kaitlin H., Timlin, Colleen, Landsburg, Daniel, Winter, Allison, Nasta, Sunita D., Bachow, Spencer H., Schuster, Stephen J., Dorsey, Colleen, Svoboda, Jakub, Barr, Paul, Ujjani, Chaitra S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927982/
https://www.ncbi.nlm.nih.gov/pubmed/29419429
http://dx.doi.org/10.3324/haematol.2017.182907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927982/
https://www.ncbi.nlm.nih.gov/pubmed/29419429
http://dx.doi.org/10.3324/haematol.2017.182907

Ejemplares similares